MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR T cell therapy program for autoimmune diseases.
Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback